Estrogen receptor mutations and functional consequences for breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Estrogen receptor alpha (ERα)-positive breast cancer often develops resistance to endocrine therapy, leading to disease recurrence and metastasis.
• Mechanisms of endocrine resistance include genetic alterations in estrogen receptors (ERs), resulting in altered protein sequences.
• Point mutations in the ESR1 gene, encoding ERα, can lead to a constitutively active receptor, promoting tumor cell survival independent of hormone stimulation.

Purpose of the Study:

• To investigate the role of ESR1 point mutations in endocrine resistance in ERα-positive metastatic breast cancer.
• To understand how ESR1 mutations contribute to the evasion of hormonal treatments.
• To identify potential therapeutic strategies targeting ER signaling in recurrent and metastatic disease.

Main Methods:

• Analysis of ESR1 gene mutations in patient tumor samples.
• Assessment of ERα protein conformation and coactivator interactions in the presence of mutations.
• Evaluation of the impact of ESR1 mutations on ER signaling pathways and tumor cell behavior.

Main Results:

• ESR1 point mutations were frequently identified in metastatic breast tumors resistant to endocrine therapy.
• These mutations alter ERα conformation, leading to increased coactivator interaction and constitutive receptor activity.
• Mutated ERα promotes tumor cell proliferation and survival, contributing to treatment refractoriness.

Conclusions:

• ESR1 point mutations are a significant mechanism of endocrine resistance in ERα-positive metastatic breast cancer.
• Targeting the constitutively active ERα resulting from ESR1 mutations may offer novel therapeutic avenues.
• Further research into strategies to control ER signaling in patients with recurrent and metastatic disease is warranted.